These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33807011)

  • 1. Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy.
    Wendel P; Reindl LM; Bexte T; Künnemeyer L; Särchen V; Albinger N; Mackensen A; Rettinger E; Bopp T; Ullrich E
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33807011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
    Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
    Front Immunol; 2019; 10():2816. PubMed ID: 31849984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
    Rezvani K; Rouce RH
    Front Immunol; 2015; 6():578. PubMed ID: 26635792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
    Rotolo R; Leuci V; Donini C; Cykowska A; Gammaitoni L; Medico G; Valabrega G; Aglietta M; Sangiolo D
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC; Hui KM
    Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
    Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
    Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer cellular immunotherapies derived from umbilical cord blood.
    Balassa K; Rocha V
    Expert Opin Biol Ther; 2018 Feb; 18(2):121-134. PubMed ID: 29103317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox.
    Xiao J; Zhang T; Gao F; Zhou Z; Shu G; Zou Y; Yin G
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
    Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
    BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
    Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
    Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.